Crystalline forms of MNK inhibitors

The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione:The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, incl...

Full description

Saved in:
Bibliographic Details
Main Authors Ernst, Justin T, Reich, Siegfried H, Webber, Stephen E, Xiang, Alan X, Borer, Bennett C, Sperry, Samuel, Wilson, Jo Ann Z, Sprengeler, Paul A
Format Patent
LanguageEnglish
Published 28.09.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione:The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
Bibliography:Application Number: US201916661507